EREG and cancer: An alternative approach, unlike the EMCT, we suspect, which is supported by the observation with CAF-derived epiregulin,172 CAF-derived periostin177 or CAF-secreted uPA,175 is that the dual targeting of the key biomarker in CAFs and its vital downstream effector of MAPK signaling axis in cancer cells may optimize the efficacy of blocking the crosstalk between CAFs and cancer cells in targeted therapy.